Continuous secretion of INAVA‐enriched EVs derived from ovarian cancer cells transfers INAVA mRNA to NOFs within the TME, thereby activating the INAVA/HMGA2/STAT3 axis and promoting NOF activation. Here, STAT3 is linked to ovarian carcinoma.